Patent · US Expired

Recombinant AAV vectors for gene therapy of hemophilia A

US6797505B2 · kind B2 · utility

5Cited by
6References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 27, 1998
Grant dateSep 28, 2004
Priority date—
Expiry dateMay 27, 2018

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The instant invention provides methods and materials for expressing a polypeptide with factor VIII activity comprising administering an rAAV vector encoding a truncated version of human factor VIII, containing, for example, a 90 kD heavy chain of factor VIII fused to a light chain of factor VIII.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.